ライフサイエンスコーパス: neoadjuvant

1 ents with HER2-positive breast cancer in the neoadjuvant, adjuvant, and metastatic settings; however,

2 Prior neoadjuvant/adjuvant antiestrogen therapy was allowed.

3 -Ang2, anti-Ang2/Ang1, anti-Tie2) to improve neoadjuvant/adjuvant chemotherapies for TNBC.

4 umab (an anti-Ang2 antibody) as an add-on to neoadjuvant/adjuvant chemotherapy.

5 cer whose treatment was randomly assigned to neoadjuvant AI therapy with anastrozole, exemestane, or

6 In patients who completed neoadjuvant AI, stratified Cox modeling was used to asse

7 cohort of ER(+) breast cancers treated with neoadjuvant anastrozole.

8 0) operable breast cancer, who had completed neoadjuvant and adjuvant chemotherapy plus trastuzumab w

9 be more effective and may be recommended as neoadjuvant and adjuvant chemotherapy.

10 his lethal disease.Significance: Coordinated neoadjuvant and adjuvant immunotherapies reduce the risk

11 the efficacy of IRE plus chemotherapy in the neoadjuvant and adjuvant or second-line setting compared

12 treatment consisting of chemotherapy in the neoadjuvant and adjuvant settings, along with surgical i

13 When trials were grouped considering neoadjuvant and adjuvant therapies and surgery alone, ne

14 or randomized controlled trials reporting on neoadjuvant and adjuvant therapies was conducted.

15 ER2-positive breast cancer and had completed neoadjuvant and adjuvant trastuzumab therapy up to 2 yea

16 and tolerability was similar across groups (neoadjuvant and adjuvant treatment periods combined).

17 s were given radiotherapy with 3-6 months of neoadjuvant and concurrent androgen suppression.

18 .04 to 1.05) but decreased significantly for neoadjuvant and metastatic trials (OR, 0.62; 95% CI, 0.5

19 %, 24%, and 24% of participants in adjuvant, neoadjuvant, and metastatic trials were age >/= 65 years

20 ith significantly lower clinical response to neoadjuvant anti-HER2 therapy in HER2(+) breast cancer p

21 f local symptoms, and may be considered as a neoadjuvant approach to improve resection rates and outc

22 (Ki67) level was > 10% after 2 to 4 weeks of neoadjuvant aromatase inhibitor (AI) therapy.

23 tumours sampled before and after 4 months of neoadjuvant aromatase inhibitor (NAI) treatment.

24 receptors (EGFR) ((177)Lu-T-AuNP) as a novel neoadjuvant brachytherapy for LABC.

25 ults are promising for their application for neoadjuvant brachytherapy of LABC.

26 ta sets and pretreatment data on Taxol-based neoadjuvant breast cancer therapy from multiple sources,

27 Only neoadjuvant, but not adjuvant treatment with a PD-1 anta

28 nded phase 2 dose of veliparib combined with neoadjuvant capecitabine and radiotherapy.

29 trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthr

30 squamous cell or adenocarcinoma and planned neoadjuvant chemoradiation (5- fluorouracil, cisplatin,

31 icantly better for cN+ patients who received neoadjuvant chemoradiation (hazard ratio, 0.52; 95% CI,

32 the 1309 patients, 41.2% (n = 539) received neoadjuvant chemoradiation and 47.2% (n = 618) were cN+.

33 patients with esophageal cancer treated with neoadjuvant chemoradiation and esophagectomy in the Nati

34 ine whether adjuvant chemotherapy (AC) after neoadjuvant chemoradiation and esophagectomy is associat

35 AC after neoadjuvant chemoradiation and esophagectomy is associat

36 of AC, the benefit of systemic therapy after neoadjuvant chemoradiation and esophagectomy is unclear.

37 Alternative chemotherapy regimens and neoadjuvant chemoradiation are being investigated to imp

38 M0 were divided into 2 treatment groups: (1) neoadjuvant chemoradiation followed by surgery and (2) s

39 tients were identified, of whom 539 received neoadjuvant chemoradiation followed by surgery and 770 r

40 The 3-year OS was better for neoadjuvant chemoradiation followed by surgery compared

41 Patients without response to neoadjuvant chemoradiation for esophageal cancer have no

42 While neoadjuvant chemoradiation for esophageal cancer improve

43 Neoadjuvant chemoradiation for stage II/III rectal cance

44 arker(s) for histopathologic non-response to neoadjuvant chemoradiation in esophageal cancer.

45 have significant implications on the use of neoadjuvant chemoradiation in patients with cN- disease.

46 Neoadjuvant chemoradiation is currently the preferred ma

47 wever, patients with cN- tumors treated with neoadjuvant chemoradiation plus surgery do not derive a

48 Fluoropyrimidine-based neoadjuvant chemoradiation was associated with a complet

49 nocarcinoma from 2010 to 2014, who underwent neoadjuvant chemoradiation, surgical resection, and adju

50 al adenocarcinoma benefit significantly from neoadjuvant chemoradiation.

51 ions were seen in the subgroup that received neoadjuvant chemoradiation.

52 whether a longer interval between the end of neoadjuvant chemoradiotherapy (CRT) and surgery is assoc

53 ce: Pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) may be a clinical pr

54 tumor extent in the resection specimen after neoadjuvant chemoradiotherapy (nCRT) and to assess its p

55 tumor extent in the resection specimen after neoadjuvant chemoradiotherapy (nCRT) and to assess its p

56 d (LNY) on survival in patients treated with neoadjuvant chemoradiotherapy (nCRT) followed by esophag

57 Neoadjuvant chemoradiotherapy (nCRT) followed by surgery

58 esophageal or junctional cancer who received neoadjuvant chemoradiotherapy (nCRT) followed by surgery

59 Neoadjuvant chemoradiotherapy (nCRT) followed by surgery

60 Adequate prediction of tumor response to neoadjuvant chemoradiotherapy (nCRT) in esophageal cance

61 6-2012 National Cancer Database who received neoadjuvant chemoradiotherapy followed by surgical resec

62 X101 as a modality to improve the outcome of neoadjuvant chemoradiotherapy for rectal cancer treatmen

63 X101 as a modality to improve the outcome of neoadjuvant chemoradiotherapy for rectal cancer treatmen

64 t) samples from rectal cancer patients after neoadjuvant chemoradiotherapy.

65 with three different types of commonly used neoadjuvant chemotherapies: anthracycline alone, anthrac

66 al after receiving taxane plus anthracycline neoadjuvant chemotherapy (MD Anderson-NeoACT: HR 0.68, 9

67 The increasing use of neoadjuvant chemotherapy (NAC) for operable breast cance

68 t of rising bilateral mastectomy rates among neoadjuvant chemotherapy (NAC) recipients in California.

69 onse (pCR) in women undergoing breast cancer neoadjuvant chemotherapy (NAC).

70 strates a pathologic tumor response (pTR) to neoadjuvant chemotherapy (NAC).

71 dvanced ovarian cancer who were treated with neoadjuvant chemotherapy (NACT) compared with primary cy

72 ts of primary cytoreductive surgery (PCS) vs neoadjuvant chemotherapy (NACT) for advanced-stage epith

73 y if percutaneous biopsy of the breast after neoadjuvant chemotherapy (NCT) indicates pCR in the brea

74 ly changes in blood flow (BF) in response to neoadjuvant chemotherapy and evaluated with (15)O-water

75 stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are

76 with limited metastatic disease who received neoadjuvant chemotherapy and proceeded to surgery showed

77 ith pathologic complete response (pCR) after neoadjuvant chemotherapy and to explore the association

78 hologic response and lymph node status after neoadjuvant chemotherapy are prognostic in patients trea

79 on patients with breast cancer treated with neoadjuvant chemotherapy at The University of Texas MD A

80 Neoadjuvant chemotherapy before surgery improves surviva

81 Patients receiving neoadjuvant chemotherapy between 1997 and 2005 were iden

82 ncers who underwent breast MR imaging before neoadjuvant chemotherapy between April 10, 2008, and Mar

83 Early metabolic change during neoadjuvant chemotherapy can predict pathologic response

84 MD Anderson taxane plus anthracycline-based neoadjuvant chemotherapy cohort (MD Anderson-NeoACT; n=5

85 ve-ACT; n=697), the Nottingham anthracycline neoadjuvant chemotherapy cohort (Nottingham-NeoACT; n=20

86 Neoadjuvant chemotherapy comprising cisplatin, doxorubic

87 of biopsy-proven node-positive patients with neoadjuvant chemotherapy could safely permit sentinel ly

88 tients in ACOSOG Z1031B who were switched to neoadjuvant chemotherapy experienced a pCR (5.7%; 95% CI

89 primary treatment: either primary surgery or neoadjuvant chemotherapy followed by interval surgery.

90 The patient was advised to undergo neoadjuvant chemotherapy followed by radical cystectomy

91 He received four cycles of cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy

92 al junction adenocarcinoma who have received neoadjuvant chemotherapy followed by transthoracic esoph

93 ve the potential to help predict response to neoadjuvant chemotherapy for breast cancer as early as c

94 carboplatin (PTX/CBP) regimen, an effective neoadjuvant chemotherapy for breast cancer patients.

95 mental regimens in combination with standard neoadjuvant chemotherapy for breast cancer.

96 to first-line therapy, 31 patients received neoadjuvant chemotherapy for localized/locally advanced

97 To evaluate the risk of neoadjuvant chemotherapy for surgical morbidity after ma

98 T0-4N1-2 breast cancer patients treated with neoadjuvant chemotherapy from 2009 to 2011.

99 her increasing the duration and intensity of neoadjuvant chemotherapy further improved survival compa

100 mors that demonstrated a good response after neoadjuvant chemotherapy had significantly lower (18)F-F

101 trates that breast cancer patients receiving neoadjuvant chemotherapy have no increased risk for surg

102 predicts better response to PTX/CBP regimen neoadjuvant chemotherapy in breast cancer patients, who

103 iated with pathological complete response to neoadjuvant chemotherapy in ER-negative disease, suggest

104 urtosis appears to be associated with pCR to neoadjuvant chemotherapy in non-triple-negative breast c

105 Our data merit further research into neoadjuvant chemotherapy in the setting of CRS and HIPEC

106 ature was associated with better response to neoadjuvant chemotherapy in TNBC (P < 0.0001) but not in

107 and a predictive marker for the response to neoadjuvant chemotherapy in TNBC, implying a potential r

108 with sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy in women presenting with node-p

109 Neoadjuvant chemotherapy is among variables identified a

110 Before neoadjuvant chemotherapy is delivered, all patients shou

111 clinical interest of axillary staging after neoadjuvant chemotherapy is increasing and this approach

112 ome sequencing of samples obtained following neoadjuvant chemotherapy is representative of the genomi

113 treatment involving radical cystectomy with neoadjuvant chemotherapy offers the best chance for cure

114 ially resectable disease, may receive either neoadjuvant chemotherapy or primary cytoreductive surger

115 d adaptive randomization to compare standard neoadjuvant chemotherapy plus the tyrosine kinase inhibi

116 Neoadjuvant chemotherapy reduces the need for axillary l

117 I or II breast cancer receiving adjuvant or neoadjuvant chemotherapy regimens excluding sequential o

118 Although neoadjuvant chemotherapy remains the preferred approach

119 mor regression score in NSCLC patients under neoadjuvant chemotherapy than algorithms and methods usi

120 tratifies patients with respect to LRR after neoadjuvant chemotherapy than presenting clinical stage

121 Such patients are excluded from neoadjuvant chemotherapy trials and pooled with patients

122 quisition to monitor breast tumor DeltaBF to neoadjuvant chemotherapy using (18)F-FDG PET/CT.

123 mor pathology) for assessing prognosis after neoadjuvant chemotherapy using pretreatment clinical sta

124 data on both types of scan before and after neoadjuvant chemotherapy were analyzed regarding SUVmax,

125 negative breast cancer and an indication for neoadjuvant chemotherapy were prospectively included.

126 She received neoadjuvant chemotherapy with doxorubicin plus cyclophos

127 ched propensity analysis was performed using neoadjuvant chemotherapy within 30 days of surgery as tr

128 positive breast cancer patients treated with neoadjuvant chemotherapy, BCSS and OS were associated wi

129 ment consisted of a multimodal protocol with neoadjuvant chemotherapy, enucleation, orbital external-

130 equired to make definitive conclusions about neoadjuvant chemotherapy, onset of PMs, and mucinous his

131 The patient had multiple concerns regarding neoadjuvant chemotherapy, particularly toxicities, espec

132 between metabolic response after 2 cycles of neoadjuvant chemotherapy, pCR, and outcome in patients r

133 In patients treated with neoadjuvant chemotherapy, TLS density was similar, but G

134 Patients were treated with neoadjuvant chemotherapy, transthoracic esophagectomy, a

135 or extensive residual disease (n = 11) after neoadjuvant chemotherapy, with cases from The Cancer Gen

136 Molecular analysis of the tumor stroma in neoadjuvant chemotherapy-treated human desmoplastic canc

137 negative tumors resected from patients after neoadjuvant chemotherapy.

138 loc 2-field lymphadenectomy in patients post neoadjuvant chemotherapy.

139 elp predict the response of breast cancer to neoadjuvant chemotherapy.

140 disease (POST-TEXT) stages III and IV after neoadjuvant chemotherapy.

141 outcomes in a node-positive cohort receiving neoadjuvant chemotherapy.

142 he Ki67 was > 10%, patients were switched to neoadjuvant chemotherapy.

143 asets on breast cancer patients who received neoadjuvant chemotherapy.

144 deally to no visible disease) should receive neoadjuvant chemotherapy.

145 surgery and axillary dissection (ALND) after neoadjuvant chemotherapy.

146 surgery reduces the FNR of SLN surgery after neoadjuvant chemotherapy.

147 performed at baseline and after 2 cycles of neoadjuvant chemotherapy.

148 complete response (pCR) is not reached after neoadjuvant chemotherapy.

149 or tripe negative breast cancer resistant to neoadjuvant chemotherapy.

150 ns of BRCA score with genome instability and neoadjuvant chemotherapy.

151 c survival outcomes in patients treated with neoadjuvant chemotherapy.

152 le exome sequencing of matched pre- and post-neoadjuvant cisplatin-based chemotherapy primary bladder

153 standard treatment of MIBC (cT2-T4a N0M0) is neoadjuvant cisplatin-based combination chemotherapy fol

154 -NeoACT; n=508), and the multicentre phase 2 neoadjuvant clinical trial cohort (phase 2 NeoACT; NCT00

155 Utilizing tumor specimens from a novel neoadjuvant clinical trial, we show that increased expre

156 usion criteria were prospective, randomized, neoadjuvant clinical trials that reported response rates

157 is associated with similar response rates as neoadjuvant combination chemotherapy but with significan

158 the assessment of complete response (CR) to neoadjuvant combined chemotherapy and radiation therapy

159 therapies showed a superior effectiveness of neoadjuvant CRT and surgery compared with surgery alone

160 val longer than 6 to 8 weeks from the end of neoadjuvant CRT and surgery significantly improved the p

161 ns: Included patients successfully completed neoadjuvant CRT followed by esophagectomy.

162 Neoadjuvant CRT followed by surgery compared with surger

163 This network meta-analysis showed neoadjuvant CRT followed by surgery to be the most effec

164 be focused on developing the most effective neoadjuvant CRT regimens for both adenocarcinomas and sq

165 After this neoadjuvant CRT, surgical exploration is undertaken 6 to

166 o receive either surgery alone (N = 2459) or neoadjuvant CT (N = 1332), RT (N = 58), and CRT (N = 119

167 e randomly allocated patients 1:1 to receive neoadjuvant CT-P6 or reference trastuzumab intravenously

168 randomly assigned (1:1:1:1) to receive four neoadjuvant cycles of trastuzumab (8 mg/kg loading dose,

169 on day 1 of cycles 2-8) in conjunction with neoadjuvant docetaxel (75 mg/m(2) on day 1 of cycles 1-4

170 She received neoadjuvant dose-dense doxorubicin, cyclophosphamide, an

171 INTERPRETATION: Four cycles of neoadjuvant ECX compared with two cycles of CF did not i

172 Objective: To evaluate the effect of neoadjuvant endocrine therapy (NET) on the response rate

173 cancer cells in clinical specimens following neoadjuvant endocrine therapy and in HT refractory metas

174 Conclusions and Relevance: Neoadjuvant endocrine therapy, even as monotherapy, is a

175 ients in arm B received at least 4 cycles of neoadjuvant FLOT and proceeded to surgical resection if

176 The rate of sepsis was 0.37% in the neoadjuvant group versus 0.46% in those that were not (P

177 return to the operating room was 5.7% in the neoadjuvant group versus 5.2% in those that were not (P

178 Neoadjuvant imatinib therapy should be considered for pa

179 ents in the Dutch GIST registry treated with neoadjuvant imatinib.

180 atients to evaluate for an early response to neoadjuvant imatinib.

181 ment decisions in GIST patients treated with neoadjuvant intent.

182 andard of care in GIST patients treated with neoadjuvant intent.

183 Neoadjuvant lapatinib therapy in HER2(+) breast tumors l

184 adjuvant trials but worsening of accrual for neoadjuvant/metastatic trials.

185 Design, Setting, and Participants: The neoadjuvant NeoALTTO trial randomized 455 women with HER

186 The neoadjuvant NeoALTTO trial randomized 455 women with HER

187 to clinical trials in which patients undergo neoadjuvant or a surgery-first approach based on their t

188 eta-analysis compared overall survival after neoadjuvant or adjuvant chemotherapy (CT), radiotherapy

189 tion performance status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of br

190 In gemcitabine-treated mice, neoadjuvant PD-1 blockade followed by adjuvant inhibitio

191 ological complete response) and suggest that neoadjuvant pertuzumab is beneficial when combined with

192 lysis of the NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showe

193 Patients and Methods In this prospective, neoadjuvant, phase II trial, 375 patients with early bre

194 nd may guide optimal timing of treatments in neoadjuvant (presurgical) and adjuvant (postsurgical) se

195 Therefore, the possible impact of neoadjuvant pretreatment in locally advanced tumors shou

196 patients (5.0%) received incomplete doses of neoadjuvant radiation.

197 ated with a significantly better response to neoadjuvant radio/chemotherapy of the patients.

198 Neoadjuvant radio/chemotherapy regimens can markedly imp

199 valuated as a novel predictive biomarker for neoadjuvant radio/chemotherapy responses.

200 sponse (pCR; ypT0N0) of a rectal tumor after neoadjuvant radiochemotherapy (RCT) is associated with a

201 ignificantly higher in patients who received neoadjuvant radiotherapy (20.0% vs 0%; P = 0.040), which

202 owever, the effect of incomplete delivery of neoadjuvant radiotherapy is unclear.

203 Evidence demonstrates that adding neoadjuvant radiotherapy to surgery offers better local

204 Neoadjuvant radiotherapy was associated with a significa

205 herlands in 2011, with almost routine use of neoadjuvant radiotherapy, shows that one third of anasto

206 Patients who were eligible for surgery after neoadjuvant RCT were randomly assigned to definitive RCT

207 We did a phase 3 trial to assess a neoadjuvant regimen for HER2-positive breast cancer that

208 found improved responses in the presurgical neoadjuvant setting but no benefits in the postsurgical

209 cancer, the role of endocrine therapy in the neoadjuvant setting is unclear.

210 ion therapy have already been adopted in the neoadjuvant setting where treatment toxicity will not be

211 fectiveness for breast cancer, mainly in the neoadjuvant setting.

212 -based therapy in pre-clinical models and in neoadjuvant settings.

213 clinical trial (NCT00715104), we found that neoadjuvant sipuleucel-T increased the number of activat

214 ictive biomarkers to personalize the optimal neoadjuvant strategy for ER+ breast cancer.

215 d remains a potential confounding factor for neoadjuvant study design.

216 We did surgery within 3-6 weeks of the final neoadjuvant study drug dose, followed by an adjuvant tre

217 INTERPRETATION: Traditional neoadjuvant systemic chemotherapy plus dual HER2-targete

218 eters in the assessment of tumor response to neoadjuvant systemic therapy (NST) in patients with brea

219 Randomized clinical trials of neoadjuvant systemic therapy for breast cancer may help

220 The use of neoadjuvant systemic therapy in the treatment of breast

221 illary surgery, or who received preoperative/neoadjuvant systemic therapy may be offered SNB.

222 tients with axillary nodal involvement after neoadjuvant systemic therapy should receive PMRT.

223 ne PET/CT before and after the completion of neoadjuvant systemic therapy.

224 ne PET/CT before and after the completion of neoadjuvant systemic therapy.

225 positive/HR-positive trial demonstrates that neoadjuvant T-DM1 (with or without ET) given for only 12

226 nt and adjuvant therapies and surgery alone, neoadjuvant therapies combined with surgery compared wit

227 studied during the last decade with various neoadjuvant therapies including chemotherapy and combina

228 A subgroup analysis of neoadjuvant therapies showed a superior effectiveness of

229 fy target pathways that may be exploited for neoadjuvant therapies.

230 erall survival between patients who received neoadjuvant therapy (NAT) followed by resection and thos

231 ic leakage at any time during follow-up were neoadjuvant therapy (odds ratio 2.85; 95% confidence int

232 iopsy-confirmed metastasis before initiating neoadjuvant therapy allows for evaluation of response in

233 pathologic complete response rates (pCRs) to neoadjuvant therapy and improve progression-free surviva

234 ediastinum and around the celiac trunk after neoadjuvant therapy and resection does not alter the TNM

235 o not achieve a pCR might still benefit from neoadjuvant therapy enabling breast-conserving surgery.

236 Neoadjuvant therapy experiments involved treating establ

237 age range, 45-70 years) scheduled to undergo neoadjuvant therapy for breast cancer underwent ultrason

238 al, a multicenter, adaptive phase 2 trial of neoadjuvant therapy for high-risk clinical stage II or I

239 rderline resectable PC and, at some centers, neoadjuvant therapy has been extended to patients with r

240 Neoadjuvant therapy is recommended for patients with bor

241 irinox is a valuable treatment option in the neoadjuvant therapy of PDAC.

242 f success in a confirmatory phase 3 trial of neoadjuvant therapy reached a prespecified threshold for

243 igated as emerging techniques for evaluating neoadjuvant therapy response for patients with primary b

244 atients with resected pT3 tumors and without neoadjuvant therapy was analyzed.

245 able site of EHD, and progression of CRLM on neoadjuvant therapy were associated with overall surviva

246 changes in (18)F-fluciclovine avidity after neoadjuvant therapy were compared to breast cancer thera

247 y with en bloc 2-field lymphadenectomy after neoadjuvant therapy were included, and survival was anal

248 with soft-tissue sarcomas who had undergone neoadjuvant therapy were reviewed by two readers during

249 Aim of the study was the evaluation of neoadjuvant therapy with a focus on Folfirinox.

250 Neoadjuvant therapy with chemotherapy or chemoradiothera

251 rapy and/or chemoradiation prior to surgery (neoadjuvant therapy) is increasingly recognized as the p

252 predicted response to fluoropyrimidine-based neoadjuvant therapy, and implications of germline altera

253 fter controlling for comorbidity, receipt of neoadjuvant therapy, and nodal involvement, a longer sur

254 h node metastasis, reduced responsiveness to neoadjuvant therapy, and reduced overall survival.

255 stages I to III HER2-positive breast cancer, neoadjuvant therapy, and reports of both pCR and an even

256 or age, comorbidity, tumor stage, histology, neoadjuvant therapy, and surgeon volume.

257 Patients who complete all intended neoadjuvant therapy, including surgery, experience an ov

258 After neoadjuvant therapy, patients underwent axillary surgery

259 ession, adjusted for age, sex, co-morbidity, neoadjuvant therapy, tumour stage, tumour histology, sur

260 (P = 0.02) from 16% at diagnosis to 31% post-neoadjuvant therapy, with loss of LBM (-3.0 +/- 5.4 kg,

261 ches combined terms for "breast cancer" and "neoadjuvant therapy," with no limit on publication date.

262 A minority (17.0%) had neoadjuvant therapy.

263 e may increase the probability of completing neoadjuvant therapy.

264 esection, of whom 88.8% received any form of neoadjuvant therapy.

265 uch as stage, tumor location, and receipt of neoadjuvant therapy.

266 to high-risk patients who have not received neoadjuvant therapy.

267 r patients according to their sensitivity to neoadjuvant therapy.

268 ween 14 days and 6 weeks after completion of neoadjuvant therapy.

269 ver Disease (MELD) score >10, and absence of neoadjuvant transarterial chemoembolization (TACE).

270 ients received six cycles (every 3 weeks) of neoadjuvant trastuzumab emtansine plus pertuzumab (trast

271 increased lymphatic vessels found in 70% of neoadjuvant treated patients.

272 cal signatures of residual cancer cells from neoadjuvant-treated breast cancer patients.

273 on was the most common wound event, 2.24% in neoadjuvant-treated versus 2.45% in those that were not

274 ell carcinoma vs adenocarcinoma) and type of neoadjuvant treatment (chemotherapy vs radiochemotherapy

275 Thirty patients received neoadjuvant treatment (NAT = 20%); 41 had venous resecti

276 achieved pCR and disease-free survival after neoadjuvant treatment according to BRCA1 and BRCA2 germl

277 er 2001 and June 2015, 575 patients received neoadjuvant treatment and were scheduled for resection a

278 ts with unresectable tumors or who underwent neoadjuvant treatment before surgery.

279 evaluate how pathologic disease response to neoadjuvant treatment impacts this effect.

280 tatic sites, disease burden, and response to neoadjuvant treatment in each disease setting.

281 valence of CT-P6 to reference trastuzumab in neoadjuvant treatment of HER2-positive early-stage breas

282 Neoadjuvant treatment offers a significant survival bene

283 Exclusion criteria were neoadjuvant treatment or pancreatitis as only diagnosis.

284 ith primary surgery (S, n = 193) versus with neoadjuvant treatment plus surgery (NS, n = 189).

285 e >20 mm at imaging should be considered for neoadjuvant treatment regardless of resectability.

286 Neoadjuvant treatment sequencing allows patients to rece

287 The study aim was to assess the impact of neoadjuvant treatment upon survival for cT3N0M0 esophage

288 In multivariable analysis, neoadjuvant treatment was an independent favorable progn

289 e patients undergoing surgery for PDAC after neoadjuvant treatment were analyzed (clinico-pathologica

290 , 2015, we randomly assigned 444 patients to neoadjuvant treatment with trastuzumab emtansine plus pe

291 0M0 esophageal tumors may or may not receive neoadjuvant treatment, according to their perception as

292 During neoadjuvant treatment, compared with patients receiving

293 No deaths were reported during neoadjuvant treatment.

294 and 2005 at Institut Bergonie, without prior neoadjuvant treatment.

295 obability of success in a subsequent phase 3 neoadjuvant trial within the biomarker signature in whic

296 e statistically significant for adjuvant and neoadjuvant trials only (OR, 1.05, 95% CI, 1.04 to 1.07;

297 Importance: In neoadjuvant trials, treatment of human epidermal growth

298 In neoadjuvant trials, treatment of human epidermal growth

299 This study examines the potency of neoadjuvant TSL HT combination therapy in two orthotopic

300 stratification by sex and use in adjuvant or neoadjuvant vs palliative setting.